Bayer’s (BAYRY) treatment of Alport syndrome was granted FDA orphan designation, according to a post to the agency’s site.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer price target lowered to EUR 20 from EUR 22 at HSBC
- Freight Technologies integrates with Blue Yonder’s TMS through Bayer
- Bayer’s emodepside granted FDA orphan designation
- FMC, Bayer collaborate to bring Isoflex to European markets
- Elliott gauged investor interest in Bayer’s consumer health business, FT says